Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023


The Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer diagnostics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer diagnostics partnering contract documents
  • Top cancer diagnostics deals by value


This report provides details of the latest cancer diagnostics agreements announced in the life sciences since 2016.

The report takes the reader through a comprehensive review cancer diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering cancer diagnostics partnering deals.

The report presents financial deal term values for cancer diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the cancer diagnostics partnering field; both the leading deal values and most active cancer diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 950 online deal records of actual cancer diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of cancer diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer diagnostics dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer diagnostics deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostics dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by cancer diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer diagnostics partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.


Key benefits

Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:

  • In-depth understanding of cancer diagnostics deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual cancer diagnostics contracts entered into by leading biopharma companies
  • Identify most active cancer diagnostics dealmakers since 2016
  • Insight into terms included in a cancer diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope

Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 is intended to provide the reader with an in-depth understanding and access to cancer diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

  • Trends in cancer diagnostics dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to cancer diagnostics contract documents
  • Leading cancer diagnostics deals by value since 2016
  • Most active cancer diagnostics dealmakers since 2016

In Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 report provides comprehensive access to available deals and contract documents for over 950 cancer diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023 report provides the reader with the following key benefits:


  • In-depth understanding of cancer diagnostics deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual cancer diagnostics contracts entered into by leading biopharma companies
  • Identify most active cancer diagnostics dealmakers since 2016
  • Insight into terms included in a cancer diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in cancer diagnostics dealmaking


2.1. Introduction

2.2. Cancer diagnostics partnering over the years

2.3. Most active cancer diagnostics dealmakers

2.4. Cancer diagnostics partnering by deal type

2.5. Cancer diagnostics partnering by therapy area

2.6. Deal terms for cancer diagnostics partnering

       2.6.1 Cancer diagnostics partnering headline values

       2.6.2 Cancer diagnostics deal upfront payments

       2.6.3 Cancer diagnostics deal milestone payments

       2.6.4 Cancer diagnostics royalty rates


Chapter 3 – Leading cancer diagnostics deals


3.1. Introduction

3.2. Top cancer diagnostics deals by value


Chapter 4 – Most active cancer diagnostics dealmakers


4.1. Introduction

4.2. Most active cancer diagnostics dealmakers

4.3. Most active cancer diagnostics partnering company profiles


Chapter 5 – Cancer diagnostics contracts dealmaking directory


5.1. Introduction

5.2. Cancer diagnostics contracts dealmaking directory


Chapter 6 – Cancer diagnostics dealmaking by technology type



Appendix 1 – Cancer diagnostics deals by company A-Z

Appendix 2 – Cancer diagnostics deals by stage of development



Phase I

Phase II

Phase III




Appendix 3 – Cancer diagnostics deals by deal type

Asset purchase


Bigpharma outlicensing


Collaborative R&D







Equity purchase



Joint venture





Material transfer





Spin out



Technology transfer



Appendix 4 – Cancer diagnostics deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Cancer diagnostics partnering since 2016

Figure 2: Active cancer diagnostics dealmaking activity since 2016

Figure 3: Cancer diagnostics partnering by deal type since 2016

Figure 4: Cancer diagnostics partnering by disease type since 2016

Figure 5: Cancer diagnostics deals with a headline value

Figure 6: Cancer diagnostics deals with an upfront value

Figure 7: Cancer diagnostics deals with a milestone value

Figure 8: Cancer diagnostics deals with a royalty rate value

Figure 9: Top cancer diagnostics deals by value since 2016

Figure 10: Most active cancer diagnostics dealmakers since 2016


Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, 3B Pharmaceuticals, 4bases, 4D Path, 1717 Life Science Ventures, A2 Biotherapeutics, Abbisko Therapeutics, Abbott Laboratories, Abbvie, Abcam, Abramson Cancer Center, ABX, Accudata Systems, Accuray, Accu Reference Medical Laboratory, AceCGT Life Science, Acibadem University, Acoustic MedSystems, Acrivon Therapeutics, ACT Genomics, Acupath Laboratories, Adaptiiv, Adaptive Biotechnologies, ADC Therapeutics, Advanced Accelerator Applications, Advanced Dermatology and Cosmetic Surgery Group, Advanced Nuclear Medicine Ingredients, Aetna, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, AG Mednet, Aidence, Aidoc, Ajou University Medical Center, Akoya Biosciences, Albert Einstein College of Medicine, Albert Einstein Healthcare Network, Alercell, Alibaba Health, Alivio Health, Allarity Therapeutics, Allelica, Alliance Global FZ, Alliance Global Group, Almac Diagnostics, Almac Group, Alphageneron Pharmaceuticals, Alpha Imaging, Alverno Clinical Laboratories, Ambry Genetics, America's Choice Provider Network, American Brain Tumor Association, American Health Imaging, American Oncology Network, Amgen, Amoy Diagnostics, Amplitech, AnchorDx, Angle, Angsana Molecular & Diagnostics, AnHeart Therapeutics, Anixa Biosciences, Anpac Bio-Medical Science, Anthem Bluecross, Antisoma Therapeutics, Anwa Medical, Apogenix, Applied DNA Sciences, ArcherDX, Arima Genomics, Arizona State University, AroCell, Arquer Diagnostics, Arrow Diagnostics, Artidis, ARTMS Product, Arvinas, Ashion Analytics, Asieris MediTech, ASPiRA Labs, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, AstraZeneca, Atlas Antibodies, Atrin Pharmaceuticals, Australian Nuclear Science and Technology Organisation, Avantis Medical Systems, AVEO Oncology, Avera Health, Avrobio, Axela, Aytu BioPharma, AZ Sint Lucas Hospital, BAMF Health, Baptist Health Care, Bayer, Baylor College of Medicine, Baylor Genetics, BC Cancer Agency, Becton Dickinson, BeiGene, Beijing InnoCare Pharma, Beijing Yuan Jian Health Management, Berry Oncology, Bertin Pharma, Bethyl Laboratories, Beyondspring Pharmaceuticals, Bicycle Therapeutics, Bio-Techne, bioAffinity Technologies, Biocare Medical, Biocartis, Biocept, Biodesix, Biofidelity, BioGemex, Biognosys, Biohealth Innovation, BioInvent, BioIQ, Biokosmos, Biolidics, BioLizard, Biological Dynamics, BioMark Diagnostics, BioMarker Strategies, BioNano Genomics, BioNTech, BioSkryb, Biovica, Bioyong, Bird Foundation, BL&H, Blackford, Bliss Biopharmaceutical, Blu Biotech, Bluebee, Blue Cross Blue Shield Association, BlueCross BlueShield of Tennessee, Blue Earth Diagnostics, Blueprint Medicines, BodyCheck, Boehringer Ingelheim, Boreal Genomics, BostonGene, Bostwick Laboratories, Bpifrance, Bracco Imaging, Brainomix, Breath Diagnostics, Brenus Pharma, BriaCell Therapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, Bruker, Bumrungrad International, Burning Rock, C2i Genomics, Cadila Pharmaceuticals, Calviri, Calyx, Cambridge Epigenetix, Canadian Cancer Society, Canadian Institutes of Health Research, CANbridge Pharmaceuticals, Cancer Australia, Cancer Genetics, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Targeted Technology, Capital X-ray, Capsulomics, Cardiff University, Cardinal Health, Care GB Plus, Carestream Health, Caris Life Sciences, Carolinas Medical Center (CMC), CarThera, Case Western Reserve University, Castle Biosciences, CBD Vida, CDx Diagnostics, Celcuity, Celgene, Cellgen Diagnostics, CellMax Life, Cellpath, CellSight Technologies, Celsee, Celsius Therapeutics, Centogene, Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre Leon Berard, Cepheid, Cerba HealthCare, Champalimaud Foundation, Charles River Laboratories, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, China Grand Pharma, China Grand Pharmaceutical, Chinese University of Hong Kong, Chonnam National University, Christian Doppler Research Association, Chronix Biomedical, Chugai Pharmaceutical, Circulogene, Cirrus Dx, City of Hope, Cizzle Biotech, Clarity Pharmaceuticals, Clearbridge Biomedics, ClearLight Diagnostics, Cleveland Clinic, Cleveland Diagnostics, Clinatec, Clinical Genomics, Clinical Laserthermia Systems (CLS), CloudHealth Genomics, Clovis Oncology, CNS Pharmaceuticals, Co-Diagnostics, Coeptis Pharmaceuticals, Coeptis Therapeutics, Cofactor Genomics, Colorado Melanoma Foundation, Colorado State University, Color Genomics, Columbia University, Columbia University Medical Center, ConcertAI, Concile, Congenica, Contextual Genomics, Copenhagen University Hospital, CoreBiome, Core Diagnostics India, CorePath Laboratories, Cornell University, CorTechs Labs, Crosscope, CSI Laboratories, CStone Pharmaceuticals, CureMetrix, Curium, Curta, Cyclotek, Cynvenio, Cypre, Cytogen, Daiichi Sankyo, Dako, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, Dante Labs, DaRui Biotech, DarwinHealth, DASA, David H. Koch Institute for Integrative Cancer Research, Day One Biopharmaceuticals, Debiopharm, Decipher Biosciences, deCODE Genetics, Deep Bio, Deepcell, Delphi Diagnostics, Dendreon, Denovo Biopharma, Densitas, Department of Defense, Department of Veterans Affairs, DermTech, Device Technologies, Devyser Diagnostics, DiaCarta, Diagnostica Longwood, Diannei Biotechnology, Diaprost, Dilon Diagnostics, DNAmito, Dr Risch, Dr Staber & Kollegen, DuChemBio, Duke University, Duke University Medical Center, Dxcover, DxTerity, Eastern Ontario Regional Laboratory Association, EchelonDx, Eckert & Ziegler, Edico Genome, Edinburgh Molecular Imaging, EDP Biotech, Eigen, Eisai, Elesta, Elevation Oncology, Eli Lilly, Emory University, Endoluxe, Enigma Biomedical, Enterome Bioscience, Epic, Epic Sciences, Epimune Diagnostics, Epiphany Dermatology, Epizyme, Erasmus University Medical Center, ESSA Pharma, Essen University Hospital, Eureka Eurostars, European Commission, European Health Centre Innovation, European Innovation Council, European Organization for Research and Treatment of Cancer, Everything Genetic, Exact Imaging, Exact Sciences, Exai Bio, Exosome Diagnostics, Exosome Sciences, F-Star Therapeutics, Factorial Diagnostics, Falco, Farcast Biosciences, Federal Ministry of Education and Research (BMBF), FedMed, Ferrum Health, Five Prime Therapeutics, Flagship Biosciences, Flatiron Health, FLX Bio, Focal Healthcare, Fondation Cancer, Fondatioun Kriibskrank Kanner, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Freenome, Fudan University, Fujifilm, Fujifilm medical systems, Fujirebio Diagnostics, Fulgent Genetics, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, Galaxy Health Network, Gamma Medica, GANZIMMUN Diagnostics, GE Healthcare, Genecast, GeneCentric Therapeutics, GeneNews, Genentech, GeneQuantum Healthcare, Geneseeq, GenesisCare, Genetics Institute, Genetic Technologies, Genetron Health, Geneva University Hospitals, Genmab, Genome Canada, GenomeDx, Genome Insight, Genome Institute of Singapore, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomoncology, Genoptix, Genosity, Genotests, German Cancer Research Center, German Federal Ministry of Education and Research, Gestalt Diagnostics, Gibson Oncology, Gilead Sciences, GIMDx, GlaxoSmithKline, GLG Pharma, Global Lung Cancer Coalition, Glytherix, GNS Healthcare, Goodwin Biotechnology, Google, Gotect Diagnostic, Government of Canada, Grail, Grand River Aseptic Manufacturing, Group Vida, Grupo Ferrer, Guardant Health, Guerbet, Guided Therapeutics, Gyros Protein Technologies, HalioDx, HALO Diagnostics, Halo Dx, Harbinger Health, Harvard Medical School, Harvard University, Healius, HealthCare Konnect, HealthTrust, Hebrew University of Jerusalem, Heidelberg Pharma, HekaBio, Helio Health, Helomics, Hengrui Therapeutics, Henlius Biotech, Henry Ford Health System, Henry M. Jackson Foundation, Hermes Medical Solutions, Heska, HiberCell, Hitachi, Hitachi Medical Systems Europe, Hoag Memorial Hospital Presbyterian, Holobeam Technologies, Hologic, Horizon Discovery, Horizon Europe, Hospital Clinic of Barcelona, Hospital Services, HotSpot Therapeutics, HTG Molecular Diagnostics, Huma, Humana, Hummingbird Bioscience, Huntsman Cancer Institute, Hybridyne Imaging Technologies, Ibex Medical Analytics, IBL America, IBM, IBM Watson Health, iCAD, Icahn School of Medicine at Mount Sinai, Idaho Urologic Institute, Idengene, IDEXX Laboratories, Ikonisys, Ikonopedia, Illumina, Image Analysis, Imagia Canexia Health, ImaginAb, Imaging Associates, Imagin Medical, Imanis Life Sciences, Imaware, Imbio, Imegen, ImmunID Technologies, Immunovia, IMPACT Therapeutics, ImpediMed, Imperial College London, IncellDx, Incyte, Indiana University, Indica Labs, Indigo Biosciences, Indivumed, Industrial Centre for Artificial Intelligence Research in Digital Diagnostics, Inflammatory Breast Cancer Research Foundation, Inform Diagnostics, Inivata, Innovate BC, Innovate UK, Innovative Manufacturing Cooperative Research Centre, Inovio Pharmaceuticals, InSightec, InSphero, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute of Cancer Research, Institut Gustave Roussy, Instituto Diagnostico Varelli, Institut Paoli-Calmettes, Integrated Biobank of Luxembourg, Integrated DNA Technologies, Intermountain Healthcare, International Association for the Study of Lung Cancer, International Centers for Precision Oncology Foundation, Interpace Diagnostics, Intezyne, Invenio Imaging, inviCRO, Invitae, InVivoScribe, ION Solutions, IPS Genomix, IRE Elit, IRX Therapeutics, Isotopia Molecular Imaging, Istituto Diagnostico Varelli, Item, ITM Isotopen Technologien, Janssen-Cilag, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jefferson Healthcare, Jiangsu Chia Tai Tianqing Pharmaceutical, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, JTS Health Partners, Jubilant Radiopharma, Juno Therapeutics, Kailos Genetics, Kaiser Permanente, Kanazawa University, Kantonsspital Baselland, Karolinska University Hospital, Kartos Therapeutics, Karyopharm Therapeutics, KDx Diagnostics, KEW, Kheiron Medical Technologies, Kindstar Globalgene Technology, Kite Pharma, Kiyatec, Knight Cancer Institute, Korea Pharma, Kronos Bio, KUB Technologies, Kura Oncology, Lab21, Labcyte, Lab Genomics, Laboratory Corporation of America, Lantern Pharma, Lantheus Holding, Lantheus Medical Imaging, Lawson Health Research Institute, Leap Therapeutics, Leica Biosystems, Leicester University, Leiden University, Leonie Hill Capital, LEO Pharma, Les Laboratoires Servier, Leucid Bio, Lexent Bio, LifeLabs Medical Laboratory Services, LifeOmic, Life Raft Group, LifeSensors, LifeX Ventures, Lighthouse Imaging, Lightpoint Medical, Li Ka Shing Foundation, Limaca Medical, LineaRx, Little Warrior Foundation, Loxo Oncology, Lucence, Lucid Diagnostics, Lumicell, Luminex, Lunaphore, Lunatus, Lung Cancer Alliance, Lung Cancer Initiative, Lunit, Lurie Children's Hospital of Chicago, Magle Chemoswed, Magnetic Insight, Mainz Biomed, Major Health Partners, Mammoth Biosciences, Manhattan Scientifics, MapKure, Massachusetts General Hospital, Massachusetts Life Sciences Center, Mauna Kea Technologies, Mayo Clinic, McMaster University, MD Anderson Cancer Center, MDNA Life Sciences, MDxHealth, Medexus Pharmaceuticals, med fusion, Medial EarlySign, MEDIAN Technologies, Medical College of Wisconsin, Medical Imaging, Medical University of Graz, Medidata Solutions, Medipath, Mediso, Medivation, medPhoton, Medx, Melanoma Research Alliance, Memorial Sloan Kettering Cancer Center, Menarini, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Merit Medical Systems, Merrimack Pharmaceuticals, Metabiomics, Metabolon, Metafora Biosystems, Metaoptima Technology, Mevion Medical Systems, Michelson Center, Micro-Tech Endoscopy, Microsoft, Milburn Foundation, Milenia Labs, MindPeak, Minogue Medical, Minomic, MIODx, Miraca Life Sciences, Mirati Therapeutics, miR Scientific, MiRXES, Mitra Biotech, MITRO Biotech, MobileODT, Moderna, Moldionics, Molecular Health, Molecular Targeting Technologies, Monopar Therapeutics, Morphotek, Mount Sinai Health System, Mount Sinai Services, mProbe Laboratories, MRI Interventions, MRM Proteomics, Multimmune, MultiPlan, Munich Leukemia Laboratory, Munich Technical University, Myelopro Diagnostics and Research, My Gene Counsel, Myocardial Solutions, Myriad Genetics, N-of-One, Nano-X Imaging, NanoMab Technology, NanoString Technologies, NantHealth, NantWorks, Natera, National Cancer Center, National Cancer Centre Singapore, National Cancer Institute, National Cancer Institute of Mexico, National Healthcare Services (NHS), National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging, National Institutes of Health, National Institutes of Health Clinical Center, National Organization for Rare Disorders, National Physical Laboratory, National Taiwan University Hospital, National Ultrasound, Naval Medical Research Center, Naveris, Navidea Biopharmaceuticals, NEC, Nektar Therapeutics, NeoDynamics, Neogenomics, Neosoma, Neuvogen, New Horizon Health, New Jersey Urology, Newmars Group, NewStem, New York University, Nico, Nihon Medi-Physics, Ninepoint Medical, NM Genomix, Nonacus, Nonagen Bioscience, Norgen Biotek, Norgine, Noria Therapeutics, Norsk medisinsk syklotronsenter, Northeastern University, Northwestern University, Notable Labs, Novarad, Novartis, NovaScan, NovellusDx, Novigenix, Novogene, NRG Oncology, nRichDX, NTT Data, Nuclear Diagnostic Products, Nucleix, Nucliber, Nucore Medical, NueHealth, NuProbe, NX Development, NYU Langone Medical Center, Ochin, Ohio State University, Olink Proteomics, OmiCure, Oncidium Foundation, Oncimmune, Oncimmune Ltd, OncoBeta, OncoCyte, OncoDNA, OncoGenesis, Oncoheroes Biosciences, OncoHost, Oncology Venture, OncoNano Medicine, OnCore Biopharma, OncoTracker, Oncovet, OncoVision, OncXerna Therapeutics, One Cell Diagnostics, OnLume Surgical, Ono Pharmaceutical, Ontario Institute for Cancer Research, Optellum, OracleBio, Orebro University, Oregon Health Sciences University, ORIG3N, OrigiMed, Orot+, Osaka University, Oslo University Hospital, Ospedale Pediatrico Bambino Gesu, Owkin, Owlstone Medical, Oxford Biodynamics, Oxford Nanopore Technologies, Pacific Biosciences, Paige, Panacea Pharmaceuticals, Pancreatic Cancer Action Network, PapGene, Paradigm, Paralax Life Science Group, Parthenon Therapeutics, PathAI, PathGroup, Pathnova Laboratories, Pathway Diagnostics, PAVmed, Pennsylvania State University, Pentax, PentixaPharm, Pepscan, Peregrine Market Access, PerkinElmer, Personal Genome Diagnostics, Personalis, Perthera, PetDx, PETNET Solutions, Pfizer, Pfizer Canada, PharmaLogic, PHC, PhenoVista Biosciences, Phi Life Sciences, Philips, Phillips-Medisize, Philochem, Phoenix Molecular Designs, Photocure ASA, Phytronix Technologies, PierianDx, Pierre Fabre, Pillar Biosciences, Pionyr Immunotherapeutics, Pippa Mann, PixCell Medical, Planet Innovation, Planmed, Plus Therapeutics, Point32Health, POINT Biopharma, Positive Bioscience, Precipio Diagnostics, PreciseDx, Precision for Medicine, Precision Pathology Services, Predicine, Predictive Technology Group, PrediLife, PreludeDx, Premas Life Sciences, PREMIA Holdings, Premier Inc, PreMIT, Prenetics, Preora Diagnostics, Prescient Medical, Progenetics, Progenics Pharmaceuticals, PrognomIQ, Promega, Prophase Labs, Proscia, Protagen, Protea Biosciences, Protean BioDiagnostics, ProteoMediX, Providence, Providence Saint John's Health Center, Provista Diagnostics, Puerto Rico Government, Puma Biotechnology, QED Therapeutics, Qiagen, Qlarity Imaging, QT Imaging, Qualigen, Quanterix, Quantum Leap Health Care Collaborative, Quebec Heart and Lung Institute, Queensland University of Technology, Queens University Belfast, Quest Diagnostics, Qure Healthcare, R-Pharm, Radboud University Nijmegen Medical Centre, Radiology Oncology Systems, Radiomedix, Radiopharm Theranostics, Radius Health, RadNet, Rainbow Genomics, Rarecells, Ratio Therapeutics, RAW, RayBiotech, Realm IDx, RefleXion Medical, Relay Therapeutics, Renji Hospital, Renown Institute for Health Innovation, Research Center for Molecular Medicine of the Austrian Academy of Sciences, ResearchDx, Resolution Bioscience, RevealDx, Reveal Genomics, RiboMed, Riverain Medical, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Diagnostics, Roche Molecular Systems, Rosetta Genomics, ROTOP Pharmaka, Royal Marsden Hospital, Royal Philips Electronics, SAGA Diagnostics, Saladax Biomedical, Sanofi, Sansure Biotech, Sarah Cannon Research Institute, Satisfai Health, Sayre Therapeutics, Scandion Oncology, SciBase, Scienion, Scintomics, Screenpoint Medical, Seattle Children's Hospital, Sebela Pharmaceuticals, Sebia, Sectra, Seegene, Seer, Seibersdorf Laboratories, Selexis, Self-screen, Sengenics, SEngine Precision Medicine, Sensus Healthcare, Seracare Life Sciences, Shanghai Fosun Long March Medical Science, Shanghai Pharmaceutical, Sheba Medical Center, Shenzhen Chipscreen Biosciences, Sherlock Biosciences, Shuwen Biotech, Siemens Healthineers, Signet Medical Solutions, SimonMed Imaging, Singlera Genomics, Sirona Medical, Sirtex Medical, Skane University Hospital, SkinCure Oncology, SkylineDX, Skyline Medical, Skyline Urology, Skysong Innovations, SmartBreast, Smart Medical Systems, Smilow Cancer Hospital at Yale-New Haven (SCH), Smiths Medical, Sofie Biosciences, SolaranRx, Solis Mammography, SomaLogic, Sona Nanotech, Sonic Healthcare, Sonrai Analytics, Sophia Genetics, Sorgente, Soricimed Biopharma, SouthGenetics, Spectrum Pharmaceuticals, Spectrum Solutions, SpePharm, Spesana, Sphingotec, SST Group, St. Jude Children's Research Hospital, Stand Up To Cancer, Stanford Health Care, Stanford University, Stanford University School of Medicine, Statera Biopharma, Strata Oncology, Stratasys, STRATIFYER Molecular Pathology, Stratify Genomics, Streck Laboratories, Stroke Detection Plus, Sunnybrook Research Institute, Surrey Cancer Research Institute, Susan G. Komen for the Cure, SweLife, Swift Biosciences, Swiss Institute of Allergy and Asthma Research, Synaptive Medical, Sysmex, Sysmex Inostics, T-Cure Bioscience, TaiRx, TaiRx US, Take2, Takeda Pharmaceutical, Tampere University Hospital, Tasly Pharmaceuticals, Tel Aviv University, TeleMammography Specialists, Telix Pharmaceuticals, Telo Genomics, Tempus, Teneovita Medical, Texas A&M University, The Hospital for Sick Children, The Parker Institute For Cancer Immunotherapy, Theradiag, Theragnostics, Theralink Technologies, TheraPanacea, Therapixel, Thermo Fisher Scientific, The Technical University Of Munich, Thomas Jefferson University, Three Rivers Provider Network, Threshold Pharmaceuticals, Tocagen, Todos Medical, Tor Vergata University Hospital, TP Therapeutics, TransCode Therapeutics, Transgenomic, Triad Isotopes, TrialJectory, TriSalus Life Sciences, TrovaGene, TumorGen, Turgut Ilaclari, Twist Bioscience, Tymora Analytical Operations, uBiome, UK Government, Ultivue, Unilabs, Uni Targeting Research, United Imaging Healthcare, United States Military Cancer Institute, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital Bispebjerg, University Hospital of Leuven, University Medical Center Hamburg-Eppendorf, University of Antwerp, University of Arizona, University of Arkansas, University of Augsburg, University of Barcelona, University of Birmingham, University of Bonn, University of California, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Florida, University of Greifswald, University of Heidelberg, University of Illinois, University of Lausanne, University of Leeds, University of Louisville, University of Manchester, University of Massachusetts Medical School, University of Melbourne, University of Miami, University of Michigan, University of Milano-Bicocca, University of Minnesota, University of North Carolina, University of Oulu, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rochester, University of Rostock, University of Sheffield, University of Southampton, University of South Carolina, University of Southern California, University of Sunderland, University of Surrey, University of Texas, University of Texas Health SCience Center at San Antonio, University of Texas Southwestern Medical Center, University of Virginia, University of Washington, UPMC, UroGPO, Urology Centers of Alabama, Urology San Antonio, UroPartners, USC Norris Comprehensive Cancer Center, US Oncology, US Radiology Specialists, Vanderbilt University, Varian Medical Systems, Vect-Horus, Vela Diagnostics, Ventana Medical Systems, Veracyte, Vergent Bioscience, Verily, Vermillion, VHA, Viatar CTC Solutions, Vidence, Viewpoint Molecular Targeting, ViewRay, Vigilant Biosciences, Vincere Cancer Center, Virginia Polytechnic Institute and State University, Virginia Tech Intellectual Properties, Visiopharm, Vitatex, Vizient, VolitionRX, Volpara Solutions, VuCOMP, VyGen-Bio, Vyriad, Wallace H. Coulter Foundation, Walloon Region Investment Fund, Waseda University, Washington University in St Louis, Weihai Weigao Medical Devices, Weill Cornell Medical College, Weizmann Institute, WellDyne, Wellmarker Bio, West German Study Group, Whiterabbit, Wilex, Wision AI, WuXi NextCODE Genomics, Wyss Institute, Xiamen Encheng Group, Xiel, Xylonix, Y-mAbs Therapeutics, Yale School of Medicine, Yale University, Yemaachi Biotech, Yitu Medical, York Instruments, YourRad, ZAP Surgical Systems, Zealand University Hospital, Zebra Medical Vision, Zionexa, Zomedica, zPREDICTA

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.